Pub. Date : 2013 Jun 20
PMID : 23787070
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Ponatinib (AP24534) an orally active Bcr-Abl Tyrosine Kinase Inhibitor and Bafetinib (INNO-406) have efficacy against various point mutations in the Bcr-Abl kinase. | ponatinib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |
| 2 | Ponatinib (AP24534) an orally active Bcr-Abl Tyrosine Kinase Inhibitor and Bafetinib (INNO-406) have efficacy against various point mutations in the Bcr-Abl kinase. | ponatinib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |
| 3 | Ponatinib (AP24534) an orally active Bcr-Abl Tyrosine Kinase Inhibitor and Bafetinib (INNO-406) have efficacy against various point mutations in the Bcr-Abl kinase. | ponatinib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |
| 4 | Ponatinib (AP24534) an orally active Bcr-Abl Tyrosine Kinase Inhibitor and Bafetinib (INNO-406) have efficacy against various point mutations in the Bcr-Abl kinase. | ponatinib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |